Evidera
Mireia Raluy Callado has extensive work experience in the field of research science and data analytics. Mireia started their career at IESE Business School as a Research Assistant, where they contributed to various projects related to competition policy and health economics. Mireia then joined United BioSource Corporation as a Research Associate before moving to Evidera. At Evidera, Mireia held multiple roles, including Research Scientist, Research Scientist and Director of RWE-Europe, and currently serves as the Senior Director of Research Science and Data Analytics.
Mireia Raluy Callado's education history is as follows. Mireia began their educational journey in 2000 at Universitat Pompeu Fabra, where they pursued a Bachelor of Arts (BA) degree in Economics. Mireia completed their undergraduate studies in 2004. Following this, they enrolled at The London School of Economics and Political Science (LSE) in 2004 and attained a Master of Science (MSc) degree in Economics by 2005.
This person is not in any offices
Evidera
1 followers
Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is the preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 30 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes.